BridgeBio Outlines 2027 Growth Plan at Wells Fargo

BridgeBio Pharma outlined a multi-product commercial expansion centered on three major therapeutic launches slated for 2027 during its presentation at the Wells Fargo 21st Annual Healthcare Conference. The pipeline update accompanies ongoing commercial uptake for its flagship transthyretin amyloid cardiomyopathy treatment, acoramidis.

"We think Attruby as the next gen, second generation differentiated stabilizer, will take more and more share, and more patients will start on that drug because simply put, it is a better drug," said Chinmay Shukla, Chief Business Officer, BridgeBio Pharma [according to a transcript from Investing.com].

Pipeline Strategy and 2027 Launch Timeline

The company's projected 2027 catalysts encompass three distinct drug candidates targeting rare genetic conditions. According to details shared in the corporate transcript, the upcoming slate includes:

• BBP-418 for limb-girdle muscular dystrophy type 2I.
• Encaleret for autosomal dominant hypocalcemia type 1 (ADH1).
• Infigratinib for achondroplasia.

These planned introductions are intended to broaden BridgeBio's commercial footprint beyond its initial cardiology offerings into skeletal dysplasia, endocrinology, and severe neuromuscular disorders.

Commercial Performance of Acoramidis

Market adoption of acoramidis, marketed under the brand name Attruby, forms the current foundation of BridgeBio's commercial operations. Executives noted that the therapy is generating annualized global revenue exceeding $1.0 billion, underpinned by U.S. sales of $222.0 million during the second quarter of 2024.

In the public equity markets, BridgeBio Pharma Inc (BBIO) shares traded at $72.50, down 4.71% from the previous close of $76.08, as of September 10, 2026, according to Finnhub market data. The company carries a market capitalization of $14.9 billion.

What Is at Stake for Rare Disease Therapies

The strategic emphasis on specialized rare disease treatments highlights the ongoing commercial race among biotechnology firms to secure first-mover advantages in genetically defined markets. With established blockbuster revenues from Attruby funding development pipelines, BridgeBio's ability to successfully navigate clinical milestones and regulatory approvals for its 2027 candidates will determine its transition from a single-product commercial enterprise into a diversified rare-disease platform.